Multimodal therapy including cytoreductive surgery and serplulimab may manage non-signet-ring cell ovarian metastases
New Treatment Strategy Shows Promise for Rare Colorectal Cancer Case
This case report and literature review describes a 54-year-old female with ascending colon adenocarcinoma and bilateral ovarian metastatic a…
A new multimodal approach combining surgery, chemotherapy, and immunotherapy may help manage rare cases of colorectal cancer that spread to …
Camrelizumab plus chemotherapy is cost-effective for first-line treatment of advanced squamous non-small-cell lung cancer
Immune Checkpoint Inhibitors Show Cost-Effectiveness for Lung Cancer Treatment
This network meta-analysis evaluates the cost-effectiveness of six immune checkpoint inhibitor-based first-line therapies combined with chem…
New analysis shows specific immune checkpoint inhibitor combinations may be more cost-effective than chemotherapy for advanced lung cancer p…
Serplulimab induced grade 4 checkpoint inhibitor pneumonitis in an elderly patient with SCLC and COPD
New cancer treatment causes severe lung inflammation in elderly patients
This case report describes a grade 4 serplulimab-induced checkpoint inhibitor pneumonitis in an 80-year-old man with extensive-stage small c…
A new cancer drug caused severe, life-threatening lung inflammation in an 80-year-old man with existing lung disease.
Serplulimab Combined With SOX Chemotherapy Improves Event Free Survival in Gastric Cancer
Trial shows serplulimab improves outcomes for gastric cancer patients
Neoadjuvant serplulimab plus SOX chemotherapy significantly improves event-free survival and safety profiles for PD-L1-positive gastric aden…
A new clinical trial finds that adding the drug serplulimab to chemotherapy significantly extends event-free survival for certain types of s…
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Review of immune checkpoint inhibitor-associated diabetes mellitus in two patients
Diabetes Danger Lingers Months After Cancer Treatment Ends
This narrative review and case report describes two patients with immune checkpoint inhibitor-associated diabetes mellitus. The authors synt…
• Some patients develop dangerous diabetes long after stopping immunotherapy • Helps cancer survivors using newer immune-boosting drugs • St…
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases
Rare Stomach Cancer Shrinks After New Combo Treatment
This case report and literature review describes a 67-year-old man with AFP-producing gastric adenocarcinoma and liver metastases treated wi…
A rare stomach cancer that spread to the liver shrank dramatically when doctors combined standard chemotherapy with a newer immune-boosting …
Phase II Trial Explores Serplulimab and Chemoradiotherapy for GEJ Adenocarcinoma
Can a new treatment approach improve outcomes for patients with advanced stomach cancer?
A phase II trial investigates serplulimab with mSOX and radiotherapy in 48 patients with cStage III GEJ adenocarcinoma.
A new trial combines immunotherapy, chemotherapy, and radiation to clear advanced stomach cancer before surgery, aiming for no surviving cel…